MannKind (MNKD) shares surged after HC Wainwright hiked its price target to $11 from $9, citing strong phase three Tyvaso trial results by partner United Therapeutics (UTHR). The drug improved lung function in idiopathic pulmonary fibrosis (IPF) patients, meeting its main goal. UTHR will meet the FDA this year on adding IPF to Tyvaso's label. Retail sentiment is extremely bullish.